Brief: China Medical System Says Entered Into License, Collaboration And Distribution Deal
Oct 7 (Reuters) - China Medical System Holdings Ltd
0867.HK :
* VIA UNIT ENTERED INTO LICENSE, COLLABORATION AND
DISTRIBUTION
AGREEMENT WITH BMI KOREA CO
* UNDER DEAL, GROUP GAINED EXCLUSIVE LICENSE TO DEVELOP,
REGISTER,
IMPORT AND COMMERCIALIZE BMI BOTULINUM TOXIN PRODUCT
* EXCLUSIVE LICENSE FOR MAINLAND CHINA, HONG KONG SPECIAL
ADMINISTRATIVE REGION AND MACAO SPECIAL ADMINISTRATIVE REGION
Source text for Eikon: ID:nHKSc2CrFl
Further company coverage: 0867.HK
Recent news on China Medical System Holdings
See all newsBrief: China Medical System Says CMS-D001 Granted Drug Clinical Trial Approval Notice By NMPA
Brief: China Medical System Holdings Says Dermavon Receives NMPA Approval For Lumirix NDA For Atopic Dermatitis
China Medical System climbs most in six weeks on higher profit, dividend
China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
AI shortens drug discovery to around 1 year in China, Insilico CEO says